Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Maintenance therapy following salvage autologous stem cell transplant in patients with multiple myeloma

Bone Marrow Transplantation volume 55, pages 1188–1190 (2020)Cite this article

Subjects

Autologous stem cell transplant (ASCT) remains the standard of care for eligible patients with multiple myeloma (MM) in the modern era [1]. Progression-free (PFS) and overall survival (OS) have markedly improved with the incorporation of novel agents into this strategy; however, MM remains incurable and nearly all will relapse, about 40–50% within 3 years after ASCT [1]. Salvage ASCT is a treatment option for these patients that offers a PFS and OS advantage over standard salvage therapy alone [2].

Following initial ASCT, maintenance treatment improves PFS, and possibly OS, and has largely become the standard of care in the US [3]. While many clinicians also recommend maintenance therapy for patients receiving a second ASCT for salvage, data supporting maintenance in this setting are limited. Here, we report on the outcomes of patients undergoing a second ASCT for salvage, comparing the outcomes of those who received maintenance and those who did not.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376:1311–20.

    Article  CAS  Google Scholar 

  2. Cook G, Ashcroft AJ, Cairns DA, Williams CD, Brown JM, Cavenagh JD, et al. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. Lancet Haematol. 2016;3:e340–51.

    Article  Google Scholar 

  3. McCarthy PL, Holstein SA, Petrucci MT, Richardson PG, Hulin C, Tosi P, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol. 2017;35:3279–89.

    Article  CAS  Google Scholar 

  4. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467–73.

    Article  CAS  Google Scholar 

  5. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412–20.

    Article  Google Scholar 

  6. Wang TF, Fiala MA, Cahen AF, Uy GL, Abboud CN, Fletcher T, et al. A phase II study of V-BEAM as conditioning regimen before second auto-SCT for multiple myeloma. Bone Marrow Transpl. 2014;49:1366–70.

    Article  CAS  Google Scholar 

  7. Lemieux E, Hulin C, Caillot D, Tardy S, Dorvaux V, Michel J, et al. Autologous stem cell transplantation: an effective salvage therapy in multiple myeloma. Biol Blood Marrow Tr. 2013;19:445–9.

    Article  CAS  Google Scholar 

  8. Gossi U, Jeker B, Taleghani BM, Bacher U, Novak U, Betticher D, et al. Prolonged survival after second autologous transplantation and lenalidomide maintenance for salvage treatment of myeloma patients at first relapse after prior autograft. Hematol Oncol. 2018;36:436–44.

    Article  Google Scholar 

  9. Manjappa S, Fiala MA, King J, Kohnen DA, Vij R. The efficacy of salvage autologous stem cell transplant among patients with multiple myeloma who received maintenance therapy post initial transplant. Bone Marrow Transpl. 2018;53:1483–6.

    Article  Google Scholar 

  10. Ludwig H, Durie BG, McCarthy P, Palumbo A, San Miguel J, Barlogie B, et al. IMWG consensus on maintenance therapy in multiple myeloma. Blood. 2012;119:3003–15.

    Article  CAS  Google Scholar 

  11. Baertsch MA, Schlenzka J, Mai EK, Merz M, Hillengass J, Raab MS, et al. Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma. BMC Cancer. 2016;16:290.

    Article  Google Scholar 

  12. Striha A, Ashcroft AJ, Hockaday A, Cairns DA, Boardman K, Jacques G, et al. The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial. Trials. 2018;19:169.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Washington University School of Medicine, St Louis, MO, USA

    Mark A. Fiala, Venkata Vosuri, Scott Goldsmith, Mark A. Schroeder, Armin Ghobadi, Tanya M. Wildes, Keith E. Stockerl-Goldstein & Ravi Vij

Authors
  1. Mark A. Fiala
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Venkata Vosuri
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Scott Goldsmith
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mark A. Schroeder
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Armin Ghobadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tanya M. Wildes
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Keith E. Stockerl-Goldstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ravi Vij
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ravi Vij.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fiala, M.A., Vosuri, V., Goldsmith, S. et al. Maintenance therapy following salvage autologous stem cell transplant in patients with multiple myeloma. Bone Marrow Transplant 55, 1188–1190 (2020). https://doi.org/10.1038/s41409-019-0663-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-019-0663-5

This article is cited by

Search

Advanced search

Quick links